Antony Odell, chief executive of (), discusses the company’s commercialisation push for its advanced wound care product.
Today, the AIM-listed group revealed it will be sharing the latest data on DermaPure with some of the industry’s leading professionals at the Symposium for Advanced Wound Care’s spring meeting in the US.
It follows the news of a ‘critical step’ towards regulatory sign-off for the start of clinical trials for Orthopure XT, a decellularised tendon device for the reconstruction of a torn anterior cruciate ligament – a career-threatening injury for footballers and other athletes.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE